Zbornik sestanka: Redkejše preobčutljivostne ... - Bolnišnica Golnik

NEJASNOSTIDosedanje klinične raziskave so bile opravljene pri bolnikih z astmo, ki imajo alergijoza perenialne alergene (pršica, mačji, pasji epitelij). Za sedaj ni jasna vloga tegazdravila pri bolnikih z alergijo za npr. pelode in plesni. Prav tako ni jasna vlogazdravila pri bolnikih z negativnimi kožnimi testi in koncentracijami IgE zunaj območja30-700 IU/ml.Literatura:1. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354:2689-95.2.Nopp A et al. CD-sens and clinical changens during withdrawal of Xolair after 6 years of treatment. Allergy 2007;62:1175-1181.3. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, HolgateST, Fahy JV. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.Am J Respir Crit Care Med 2004;170(6):583-93.4. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody,in patients with allergic asthma. Chest 2004; 125(4):1378-86.5. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cellFcepsilonRI expression. J Allergy Clin Immunol 2003; 112(6):1147-54.6. Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, Fowler-Taylor A, Liu J, Gupta N. Omalizumab improvesasthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111(2):278-84.7. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-relatedemergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111(1):87-90.8. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgErecombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol2001;108(2):184-90.36